ZTS•November 19, 2026 at 12:30 PM UTCPharmaceuticals, Biotechnology & Life Sciences

Zoetis Gains USDA Approval for New Poultry Vaccine, Adds to Livestock Portfolio

Read source article

What happened

Zoetis announced that the USDA has licensed its Poulvac Procerta HVT-ND-ILT vector vaccine for chickens, consolidating three disease targets into a single shot for poultry producers. This approval expands Zoetis's livestock vaccine portfolio and underscores its continued investment in poultry health, a segment that has faced recent softness in swine and poultry medications. The news, while positive, is incremental relative to the company's larger franchises in companion animals, which account for about two-thirds of revenue and are currently facing headwinds from osteoarthritis drug safety concerns and slower growth. Zoetis trades around $125, and this product milestone does not alter the fundamental picture of mid-single-digit revenue growth and a premium valuation at ~21x earnings. Investors are likely to focus on near-term catalysts such as Librela Phase IV data and 2026 guidance rather than this single license.

Implication

Investors should view this approval as a modest positive for the livestock segment, which has been a drag on recent results but where vaccines and higher-value products remain a strategic focus. The vaccine could support revenue for poultry producers, but its contribution is unlikely to be material in the near term given the scale of Zoetis's $9.3 billion revenue base. The core debate remains the recovery of the osteoarthritis monoclonal antibody franchise in the U.S., where revenue has struggled, and the company's ability to return to high-single-digit organic growth. We maintain a WAIT rating: the stock is not expensive enough to offer a compelling entry at these levels, nor cheap enough to provide significant downside protection if OA adoption disappoints further. A better entry below $110 or clearer signs of OA stabilization and growth reacceleration would improve the risk-reward.

Thesis delta

This news does not alter our investment thesis. It reinforces Zoetis's strength in livestock prevention but does not address the dominant driver of near-term uncertainty: the OA mAb franchise. We leave our WAIT rating, conviction of 3.5, trim above $150, and attractive entry at $110 unchanged.

Confidence

high